Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.
Citation: Future Science OA. 4(1):FSO249, 2018 JanPMID: 29255621Institution: MedStar Washington Hospital CenterDepartment: Medicine/Endocrinology | Pathology | Surgery/Endocrine Surgery | Surgery/General SurgeryForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2018ISSN:- 2056-5623
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 29255621 | Available | 29255621 |
Aim: To investigate biomarkers for predicting papillary thyroid cancer outcomes.
Conclusion: SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted.
Materials & methods: The expression of biomarkers (ITGA2, SYT12 and CDH3) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.
Results: SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively.
English